vs
FIRST FINANCIAL BANKSHARES INC（FFIN）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是FIRST FINANCIAL BANKSHARES INC的1.3倍（$207.3M vs $164.7M），FIRST FINANCIAL BANKSHARES INC净利率更高（44.5% vs -62.0%，领先106.5%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 12.0%），FIRST FINANCIAL BANKSHARES INC自由现金流更多（$286.0M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 12.7%）
第一金融银行股份有限公司（FFIN）是总部位于印第安纳州特雷霍特的区域银行，由第一金融集团运营。它是印第安纳州历史最悠久的全国性银行，在美国全国性银行中历史排名第五，其母公司第一金融集团也是维戈县唯一的上市企业。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
FFIN vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $164.7M | $207.3M |
| 净利润 | $73.3M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 54.4% | -54.7% |
| 净利率 | 44.5% | -62.0% |
| 营收同比 | 12.0% | 25.9% |
| 净利润同比 | 17.6% | 3.5% |
| 每股收益（稀释后） | $0.51 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $164.7M | $207.3M | ||
| Q3 25 | $161.3M | $159.9M | ||
| Q2 25 | $156.6M | $166.5M | ||
| Q1 25 | $149.0M | $139.3M | ||
| Q4 24 | $147.1M | $164.6M | ||
| Q3 24 | $139.5M | $139.5M | ||
| Q2 24 | $134.5M | $147.0M | ||
| Q1 24 | $129.6M | $108.8M |
| Q4 25 | $73.3M | $-128.6M | ||
| Q3 25 | $52.3M | $-180.4M | ||
| Q2 25 | $66.7M | $-115.0M | ||
| Q1 25 | $61.3M | $-151.1M | ||
| Q4 24 | $62.3M | $-133.2M | ||
| Q3 24 | $55.3M | $-133.5M | ||
| Q2 24 | $52.5M | $-131.6M | ||
| Q1 24 | $53.4M | $-170.7M |
| Q4 25 | 54.4% | -54.7% | ||
| Q3 25 | 39.2% | -106.9% | ||
| Q2 25 | 52.2% | -64.8% | ||
| Q1 25 | 50.4% | -102.6% | ||
| Q4 24 | 51.7% | -74.3% | ||
| Q3 24 | 48.3% | -94.6% | ||
| Q2 24 | 47.3% | -79.1% | ||
| Q1 24 | 50.0% | -151.9% |
| Q4 25 | 44.5% | -62.0% | ||
| Q3 25 | 32.4% | -112.8% | ||
| Q2 25 | 42.6% | -69.0% | ||
| Q1 25 | 41.2% | -108.5% | ||
| Q4 24 | 42.4% | -80.9% | ||
| Q3 24 | 39.7% | -95.7% | ||
| Q2 24 | 39.0% | -89.5% | ||
| Q1 24 | 41.2% | -156.8% |
| Q4 25 | $0.51 | $-1.28 | ||
| Q3 25 | $0.36 | $-1.81 | ||
| Q2 25 | $0.47 | $-1.17 | ||
| Q1 25 | $0.43 | $-1.57 | ||
| Q4 24 | $0.43 | $-1.34 | ||
| Q3 24 | $0.39 | $-1.40 | ||
| Q2 24 | $0.37 | $-1.52 | ||
| Q1 24 | $0.37 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.9B | $-80.0M |
| 总资产 | $15.4B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | — | $421.0M | ||
| Q3 25 | — | $202.5M | ||
| Q2 25 | — | $176.3M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $174.0M | ||
| Q3 24 | — | $150.6M | ||
| Q2 24 | — | $480.7M | ||
| Q1 24 | — | $112.3M |
| Q4 25 | $1.9B | $-80.0M | ||
| Q3 25 | $1.8B | $9.2M | ||
| Q2 25 | $1.7B | $151.3M | ||
| Q1 25 | $1.7B | $144.2M | ||
| Q4 24 | $1.6B | $255.0M | ||
| Q3 24 | $1.7B | $346.8M | ||
| Q2 24 | $1.5B | $432.4M | ||
| Q1 24 | $1.5B | $140.3M |
| Q4 25 | $15.4B | $1.5B | ||
| Q3 25 | $14.8B | $1.2B | ||
| Q2 25 | $14.4B | $1.3B | ||
| Q1 25 | $14.3B | $1.3B | ||
| Q4 24 | $14.0B | $1.5B | ||
| Q3 24 | $13.6B | $1.5B | ||
| Q2 24 | $13.2B | $1.6B | ||
| Q1 24 | $13.2B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $299.4M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $286.0M | $-100.8M |
| 自由现金流率自由现金流/营收 | 173.6% | -48.6% |
| 资本支出强度资本支出/营收 | 8.2% | 0.5% |
| 现金转化率经营现金流/净利润 | 4.08× | — |
| 过去12个月自由现金流最近4个季度 | $503.1M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $299.4M | $-99.8M | ||
| Q3 25 | $86.5M | $-91.4M | ||
| Q2 25 | $61.3M | $-108.3M | ||
| Q1 25 | $76.8M | $-166.5M | ||
| Q4 24 | $309.6M | $-79.3M | ||
| Q3 24 | $80.7M | $-67.0M | ||
| Q2 24 | $68.8M | $-77.0M | ||
| Q1 24 | $75.6M | $-190.7M |
| Q4 25 | $286.0M | $-100.8M | ||
| Q3 25 | $83.7M | $-92.7M | ||
| Q2 25 | $58.7M | $-110.7M | ||
| Q1 25 | $74.7M | $-167.8M | ||
| Q4 24 | $292.9M | $-79.5M | ||
| Q3 24 | $77.7M | $-68.6M | ||
| Q2 24 | $63.8M | $-79.0M | ||
| Q1 24 | $71.7M | $-193.9M |
| Q4 25 | 173.6% | -48.6% | ||
| Q3 25 | 51.9% | -58.0% | ||
| Q2 25 | 37.5% | -66.5% | ||
| Q1 25 | 50.1% | -120.5% | ||
| Q4 24 | 199.1% | -48.3% | ||
| Q3 24 | 55.7% | -49.2% | ||
| Q2 24 | 47.4% | -53.7% | ||
| Q1 24 | 55.3% | -178.2% |
| Q4 25 | 8.2% | 0.5% | ||
| Q3 25 | 1.7% | 0.8% | ||
| Q2 25 | 1.6% | 1.5% | ||
| Q1 25 | 1.4% | 1.0% | ||
| Q4 24 | 11.4% | 0.1% | ||
| Q3 24 | 2.2% | 1.2% | ||
| Q2 24 | 3.7% | 1.4% | ||
| Q1 24 | 3.0% | 3.0% |
| Q4 25 | 4.08× | — | ||
| Q3 25 | 1.65× | — | ||
| Q2 25 | 0.92× | — | ||
| Q1 25 | 1.25× | — | ||
| Q4 24 | 4.97× | — | ||
| Q3 24 | 1.46× | — | ||
| Q2 24 | 1.31× | — | ||
| Q1 24 | 1.42× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FFIN
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
